 STAMFORD, Conn., May 10, 2021 GLOBE NEWSWIRE -- SpringWorks Therapeutics, Inc. Nasdaq: SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development RD. Dr. Burgess is a physician-scientist with clinical experience in pediatrics and pediatric oncology and over 20 years of pharmaceutical industry RD leadership experience across several therapeutic areas, including oncology. Dr. Burgess will lead the RD organization as the company continues to advance its diversified targeted oncology pipeline and to expand its portfolio with additional oncology programs. He succeeds Stephen Squinto, Ph.D., who served as Acting Head of RD since the companys launch in 2017. Dr. Squinto will continue to serve on the SpringWorks Board of Directors. 